logo
Higher cancer rates linked to WWII radioactive waste in Midwestern creek

Higher cancer rates linked to WWII radioactive waste in Midwestern creek

Fox News5 days ago
NEW You can now listen to Fox News articles!
A Missouri creek has allegedly led to a higher risk of cancer in neighboring residents.
Coldwater Creek, a Missouri River tributary north of St. Louis, has been a known radioactive waste site since the 1980s.
Researchers have now confirmed that exposure to the creek, which is said to be polluted with nuclear waste from the development of the first atomic bomb, has led to an increased incidence of cancer for people who were children in the area between the 1940s and 1960s.
MAN'S DEADLY BRAIN CANCER TUMOR DISAPPEARS AFTER EXPERIMENTAL DRUG TRIAL
A study from the Harvard T.H. Chan School of Public Health, which was published in JAMA Network, analyzed the data of 4,209 participants who lived near Coldwater Creek.
The data was originally gathered for a previous study on childhood radiation exposure.
Participants who lived in the Greater St. Louis area between 1958 and 1972 shared their cancer diagnoses, which allowed researchers to calculate risk based on their proximity to the creek.
The researchers found an elevated risk of cancer in a long-term follow-up, with those who lived closest to the creek reporting a higher incidence of most cancers.
"The waste from these entities could have huge impacts on people's health, even at lower levels of exposure."
In total, 24% of study participants reported having cancer. Of those, 30% lived less than one kilometer away from the creek, 28% lived between one and five kilometers away, 25% lived between five and 20 kilometers away, and 24% lived more than 20 kilometers away.
Corresponding author Marc Weisskopf, professor of environmental epidemiology and physiology at Harvard T.H. Chan School of Public Health, commented on these findings in a press release.
CHILDREN EXPOSED TO HIGHER FLUORIDE LEVELS FOUND TO HAVE LOWER IQS, STUDY REVEALS
"Our research indicates that the communities around North St. Louis appear to have had excess cancer from exposure to the contaminated Coldwater Creek," he said.
"These findings may have broader implications — as countries think about increasing nuclear power and developing more nuclear weapons, the waste from these entities could have huge impacts on people's health, even at these lower levels of exposure."
This study accompanies Congress' passing of an expanded version of the Radiation Exposure Compensation Act (RECA), as part of President Trump's Big Beautiful Bill.
The act will allow Americans, including Coldwater Creek residents, to receive compensation for medical bills associated with radiation exposure, the researchers noted.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
Local agencies have become increasingly concerned about cancer prevalence in the area, prompting the push for further research beyond the U.S. government's acknowledgment of the pollution four decades ago.
The contamination originally occurred due to the Manhattan Project and Mallinckrodt Chemical Works, which processed and refined uranium in St. Louis, according to the study.
The radioactive material was moved out of the major U.S. city and into the more rural area near Coldwater Creek, where it was stored in uncovered drums on the ground and exposed to the elements, allowing contaminants to leach into the nearby creek.
The researchers noted that communities downstream from Coldwater Creek had potentially been exposed to the ionizing radiation during recreational activities, such as playing in the creek, and residential activities, like breathing in dust suspended from the soil when gardening.
For more Health articles, visit www.foxnews.com/health
The study did have some limitations, the researchers acknowledged, including its small sample size and reliance on self-reported cancer outcomes.
The potential carcinogenic impact of creek exposure warrants further research to confirm the findings, the team concluded.
Co-author Michael Leung, PhD, post-doctoral research fellow at Harvard's Department of Environmental Health, reflected on the findings in an interview with Fox News Digital.
"Our study found that children in the 1940s to 1960s who lived near Coldwater Creek, which was contaminated by radioactive waste from the development of the first atomic bomb, had a 44% higher risk of cancer compared to those living further than 20 kilometers away," he confirmed.
CLICK HERE TO GET THE FOX NEWS APP
"Our findings coincide with Congress passing an expanded version of the Radiation Exposure Compensation Act, and gives further credence to the health concerns of St. Louis area-residents about the contaminated creek," Leung went on.
"We hope these findings will support public health measures for affected communities, as well as ongoing efforts to remediate the creek."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

UnitedHealth Group (UNH) Responds to the Department of Justice
UnitedHealth Group (UNH) Responds to the Department of Justice

Yahoo

time24 minutes ago

  • Yahoo

UnitedHealth Group (UNH) Responds to the Department of Justice

UnitedHealth Group Incorporated (NYSE:UNH) is one of the top low volatility healthcare stocks to buy now. On July 24, UnitedHealth Group Incorporated (NYSE:UNH) released a statement responding to the Department of Justice after a review of the media reports about investigations into specific aspects of its involvement in the Medicare program. A senior healthcare professional giving advice to a patient in a clinic. UnitedHealth Group Incorporated (NYSE:UNH) stated that it has now begun complying with the formal criminal and civil requests from the Department, and has 'full confidence in its practices and is committed to working cooperatively with the Department throughout this process'. It added that UnitedHealth Group Incorporated (NYSE:UNH) has a historical record of 'responsible conduct and effective compliance,' with independent CMS audits showing that its practices are ranked 'among the most accurate in the industry.' Management stated that after a decade-long civil challenge by the Department to aspects of the company's Medicare Advantage business, 'a court-appointed Special Master concluded there was no evidence to support claims of wrongdoing'. UnitedHealth Group Incorporated (NYSE:UNH) has launched its own initiative to provide confidence and transparency to stakeholders, focusing on conducting 'third-party reviews of policies, practices, and associated processes and performance metrics for risk assessment coding, managed care practices, and pharmacy services.' UnitedHealth Group Incorporated (NYSE:UNH) provides healthcare coverage, data consultancy, and software services. It operates through the OptumRx, OptumInsight, OptumHealth, and UnitedHealthCare segments, which have solid operations. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

Clinical Case: Kidney Cancer Hides in 6-mm Breast Lesion
Clinical Case: Kidney Cancer Hides in 6-mm Breast Lesion

Medscape

time25 minutes ago

  • Medscape

Clinical Case: Kidney Cancer Hides in 6-mm Breast Lesion

A 54-year-old woman with a history of renal cell carcinoma (RCC) developed a metastatic lesion in her breast 6 years after radical nephrectomy. The lesion, initially detected via routine imaging, was confirmed as RCC by histopathology and immunohistochemistry. This case report by Aman Saswat Sahoo, a fourth-year Medicine & Surgery undergraduate at the University of Central Lancashire, School of Medicine and Dentistry, Preston, England, and colleagues, highlighted the need for meticulous diagnostic evaluation to distinguish between primary breast carcinoma and metastatic disease, particularly in patients with a history of RCC. The Patient and Her History The patient had a history of RCC that was initially treated with radical nephrectomy and no chemotherapy. She had undergone regular CT imaging since her surgery 3 years ago, and routine CT identified a 4-mm lesion in the lower outer quadrant of the right breast. No other relevant preexisting medical conditions were reported. Her medical, family, travel, allergy, social, and drug histories were unremarkable. Findings and Diagnosis A clinical examination revealed no palpable abnormalities in both breasts. Mammography revealed a 6-mm nodule in the posterolateral region of the right breast, which was absent on a prior mammogram conducted 4 years earlier. Ultrasound imaging confirmed the presence of a solid nodule measuring approximately 5 mm in size. Ultrasound evaluation correlated these findings with a 5-mm benign-appearing nodule. A core biopsy was performed, and histopathologic evaluation showed an inflammatory lesion, characterised by cells with clear cytoplasm and macrophages. Considering the initial diagnosis, immunohistochemical staining provided crucial diagnostic clarity, with positive results for PAX8, CD10, and MNF116 markers, confirming metastatic RCC. Given the patient's history, these findings confirmed the presence of metastatic RCC in the right breast. The patient was informed of the diagnosis of metastatic RCC in the right breast. Further assessment of distant sites and the potential for systemic therapy were discussed at this stage; however, it was later decided that no systemic interventions would be pursued. Although the lesion was considered minor in terms of surgical intervention, its identification is crucial as an indicator of metastatic disease. Wide local excision was performed after tagging the lesion with a radiofrequency identification tag located 3 mm inferior to the original site; no axillary surgery was performed. Postoperative histopathologic evaluation revealed a 5-mm well-circumscribed metastatic RCC. No vascular invasion, ductal carcinoma in situ, or lobular carcinoma in situ was identified. Discussion Although RCC is prominent in its ability to spread haematogenously, metastasis to the breast is extremely uncommon. The route for metastasis usually includes the migration of tumour cells from the kidneys through the inferior vena cava to the right ventricle of the heart. From here on, they enter the pulmonary circulation and eventually reach the breast. Breast metastasis from RCC is exceedingly rare, with fewer than 60 cases documented in the literature. Although the risk for RCC recurrence is highest within the first 2 years following treatment, metastases to uncommon sites, such as the breast, have been reported even a decade after the initial diagnosis and surgical intervention. 'The limited information available in the literature regarding optimal treatment strategies and patient outcomes for RCC metastasis to the breast highlights the need for further studies to better understand this condition,' the authors wrote.

Patients With Acromegaly Face Higher Cancer Risk
Patients With Acromegaly Face Higher Cancer Risk

Medscape

time25 minutes ago

  • Medscape

Patients With Acromegaly Face Higher Cancer Risk

TOPLINE: Patients with acromegaly had significantly higher odds of developing leukemia/lymphoma or ovarian, breast, lung, or other cancers, many of which occurred at younger ages than typically seen in the general population. These data underscored the urgent need to integrate cancer screening protocols into routine care for patients with acromegaly to facilitate earlier detection and intervention. METHODOLOGY: Excess growth hormone secretion in patients with acromegaly increases the levels of insulin-like growth factor, a known cancer risk factor; however, the true prevalence of cancer in these patients is not well known. Researchers conducted a retrospective cohort analysis using data from a multinational research network platform to compare cancer prevalence in individuals with acromegaly and those without the condition. Patients with acromegaly (n = 10,207; mean age at disease onset, 43.2 years; 52.9% women) were matched with 102,070 individuals from the general population without the condition. TAKEAWAY: Patients with acromegaly had a 3.3-fold increased odds of developing leukemia/lymphoma (95% CI, 2.3-4.67), a 1.9-fold increased odds of developing ovarian cancer (95% CI, 1.3-2.8), a 1.8-fold increased odds of developing breast cancer (95% CI, 1.5-2.0), 1.9-fold increased odds of developing lung cancer (95% CI, 1.5-2.3), and a 1.5-fold increased odds of developing prostate cancer (95% CI, 1.3-1.8). The onset of certain cancers, specifically ovarian, lung, liver, and neuroendocrine, occurred much earlier (3.2-7.2 years) in patients with acromegaly than in control individuals from the general population. IN PRACTICE: 'Our findings suggest that acromegaly may play a bigger role in cancer risk than previously thought, highlighting the need for increased awareness and early cancer screening in this population,' said the lead researcher in a press release. SOURCE: This study was led by Hitam Hagog Natour, MD, Thomas Jefferson University Hospital in Philadelphia. It was presented on July 14, 2025, at the ENDO 2025: The Endocrine Society Annual Meeting in San Francisco. LIMITATIONS: This study did not report any specific limitations. DISCLOSURES: This study did not report any specific funding or conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store